MedTrace Logo

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

Study of ANA001 in Moderate and Severe COVID-19 Patients

Conditions

Interventions

DRUG

Niclosamide

Niclosamide is an antihelmintic with in-vitro antiviral activity

DRUG

Placebo

Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Doug Rank, MD · NeuroBo Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2022-02-16
Completion
2022-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603924 on ClinicalTrials.gov